Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Immunome
Deal Size : Undisclosed
Deal Type : Merger
Details : The combined company will feature a synergistic platform which is expected to enable the development of best-in-class targeted cancer therapies across multiple modalities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Immunome
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Immunome
Deal Size : Undisclosed
Deal Type : Merger
Details : The combined company will feature a synergistic platform which is expected to enable the development of best-in-class targeted cancer therapies across multiple modalities.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
June 29, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Immunome
Deal Size : Undisclosed
Deal Type : Merger